GSK has received approval for its Blenrep treatment for relapsed or refractory multiple myeloma from the Ministry of Health, Labour and Welfare in Japan. This approval follows positive results from two pivotal phase III trials, Dreamm-7 and Dreamm-8, which demonstrated significant advancements in treatment outcomes for patients.
This will be welcome news to holders of GSK shares (LON: GSK), having seen a 21.24% decline in the price over the past 12 months.
In the Dreamm-7 trial, Blenrep was combined with bortezomib and dexamethasone (BVd). This combination showed improved overall survival rates and significant progression-free survival compared to standard care. The Dreamm-8 trial evaluated Blenrep with pomalidomide and dexamethasone (BPd), where similar benefits were observed in progression-free survival.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Both trials underscored the potential of these Blenrep combinations to redefine treatment outcomes. Hesham Abdullah, GSK’s Senior Vice President and Global Head of Oncology at R&D, emphasized the impact these results could have on patient care.
An additional benefit of the Blenrep treatment is its in-office administration, making it convenient for healthcare providers and patients.
This development marks a significant milestone for GSK, highlighting its ongoing commitment to advancing cancer therapies and improving patient outcomes in oncology.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
